Early Indicator definition

Early Indicator default risk score. Those borrowers with risk scores that suggest a strong statistical likelihood of continuing default, are approved for foreclosure as soon as 48 hours after expiration of the demand letter (approximately 64 calendar days delinquent).
Sample 1Sample 2Sample 3
Early Indicator default risk score. Those borrowers with risk scores that suggest a strong statistical likelihood of continuing default, are approved for foreclosure as soon as 48 hours after expiration of the demand letter (approximately 64 calendar days delinquent). B. Moderate risk with willingness and ability. Those borrowers with a moderate statistical likelihood of continuing default who demonstrate a willingness and ability to pay (as defined above), are solicited for extended (up to 6 months) repayment plans in which a portion of all past due payments are divided equally by 6 and a monthly payment schedule is established which consists of a "good faith" payment of some portion of the past due amount, one regular monthly installment and 1/6th of the remaining past due amount. C. Low risk with willingness and ability. Those borrowers with a low risk of continuing default are actively solicited for placement on a repayment plan and/or are granted additional time to resolve their financial difficulties informally in arrangement with a loan counselor. Foreclosure is not typically initiated if or until the loan becomes 90+ days delinquent and the borrower is unable or unwilling to continue to make reasonable repayment arrangements. D. Broken repayment plans. Those borrowers who are placed on extended repayment plans but fail to make their scheduled payments, are approved for foreclosure as soon as 48 hours after the payment plan is broken. All borrowers are given all reasonable opportunities to pay the total amount past due (including all contractually permitted fees and charges) prior to the expiration of the 30 day demand letters. Borrowers who fail to contact Option One collections when past due, who repeatedly break promises to pay, who have a willingness but no financial ability, or apparent financial ability but no willingness, may be referred to foreclosure at any time after the expiration of the 30-day demand letter, without regard to any other factor, but as a general rule, a loan is referred to foreclosure no later than the 120th day of delinquency. The guidelines outlined herein presuppose at least some reasonable degree of willingness and ability.
Sample 1

Examples of Early Indicator in a sentence

  • Cutaneous Mitochondrial PO2, but Not Tissue Oxygen Saturation, Is an Early Indicator of the Physiologic Limit of Hemodilution in the Pig.

  • Circulating Tumor DNA as an Early Indicator of Response to T-cell Transfer Immunotherapy in Metastatic Melanoma.

  • Because neither the record nor the law supports Packet Intelligence's recovery of pre-suit damages for any of the asserted patents, NetScout is entitled to judgment as a matter of law on this issue.V. Willfulness Finally, NetScout appeals the willfulness judgment.

  • ODS - Early Indicator and Intervention SystemResearch has identified attendance, behavior, and course performance as powerful predictors of high school completion.

  • The mortgage must have received a score of D, E, or F on the Freddie Mac Early Indicator Risk Scoring software system.

  • HIV in the Migrant and Seasonal Farmworker Population: Oral Conditions as an Early Indicator of Infection.

  • Intravenous Bisphosphonate-Related Osteonecrosis of the Jaw: Bone Scintigraphy as an Early Indicator.

  • Freddie Mac’s Ear-ly Indicator and Fannie Mae’s Risk Profiler are systems designed to manage these aspects of the process in the conforming market.34 EarlyIndicator scores collections accounts from 000 to 099 based on past payment history, credit rating, and other factors.

  • Searching for SARS-COV-2 on Particulate Matter: A Possible Early Indicator of COVID-19 Epidemic Recurrence.

  • Early Indicator events have little impact on system with partial group of the users.

Related to Early Indicator

  • KPI Target means the acceptable performance level for a KPI as set out in each KPI;

  • Performance Indicator means a measure of HSP performance for which a Performance Target is set; technical specifications of specific Performance Indicators can be found in the MSAA Indicator Technical Specifications document;

  • Development Milestone Event shall have the meaning set forth in Section 9.2(a).

  • Phase III Trial means a Clinical Trial of an investigational product in subjects that incorporates accepted endpoints for confirmation of statistical significance of efficacy and safety with the aim to generate data and results that can be submitted to obtain Regulatory Approval as described in 21 C.F.R. 312.21(c), or a comparable Clinical Trial prescribed by the relevant Regulatory Authority in a country other than the United States.

  • Second Indication means [***].

  • New Product means the Synology-branded hardware product and Synology-branded accessories contained in the original packaging Customer bought from an authorized Synology distributor or reseller. You may see our “New Product” at Product Support Status.

  • Back-Up Compound means, with reference to any particular Development Candidate or Drug Product Candidate, a Compound which (a) has the same principal mode of action (i.e., Potentiator or Corrector) as that Development Candidate or Drug Product Candidate; and (b) was among the group of Compounds, identified by VERTEX as potential additional lead molecules having the same principal mode of action, from which the Development Candidate was selected.

  • Development Milestone Payment shall have the meaning set forth in Section 9.2(a).

  • Milestone Event has the meaning set forth in Section 8.4.

  • Initial Indication means the use of a Product for the treatment of opioid addiction.

  • Milestone means an event or task described in the Implementation Plan which must be completed by the corresponding date set out in such plan;

  • First Indication means the first disease condition for which a particular Licensed Product has been approved by a Regulatory Authority.

  • Hemp product means the same as that term is defined in § 3.2-4112.

  • Phase III Clinical Study means a pivotal Clinical Study, the results of which could be used to establish safety and efficacy of a Licensed Product in the Field as a basis for Regulatory Approval or that would otherwise satisfy requirements of 21 CFR 312.21(c), or its foreign equivalent.

  • Phase III Clinical Trial means a large, controlled or uncontrolled Clinical Study that would satisfy the requirements of 21 CFR 312.21(c), intended to gather the additional information about effectiveness and safety that is needed to evaluate the overall benefit-risk relationship of the drug and to provide an adequate basis for physician labeling.

  • Milestone 1 means achievement of annual Net Sales of at least $20,000,000 during the Calendar Year ending on December 31, 2021.

  • Non-Microsoft Product means any third-party-branded software, data, service, website or product, unless incorporated by Microsoft in a Product.

  • Product Candidate means each of MYO-101, MYO-102, MYO-103, MYO-201 and MYO-301, as defined on Exhibit B, in each case in any form or formulation.

  • Replacement Product means electric generating capacity, capacity-related benefits, environmental attributes, Energy or other electric products from a generation resource other than the Facility that are provided or delivered to replace or substitute for Contract Capacity or Storage Capacity (or any Capacity-Related Benefit, Environmental Attribute, Other Electric Product, Contract Energy, or Storage Energy associated therewith), in each case, in whole or in part, pursuant to Section 4.6.

  • Phase III Clinical Trials means a Clinical Trial for the Product on sufficient numbers of patients to generate safety and efficacy data to support Regulatory Approval in the proposed therapeutic indication, conducted in accordance with current good clinical practices and in accordance with a protocol that has been reviewed by the FDA and reflects any comments or concerns raised by the same.